Two ingredients. Two mechanisms. One formula that addresses both the nausea and the fatigue of treatment — together.
Zingiber officinale · 2,000mg per serving · 5-HT3 receptor antagonist · NK1 modulator · Prokinetic agent
When SIPS is dissolved in water and sipped, active gingerols begin absorbing through the mucosal lining of the mouth and tongue — bypassing the digestive system entirely. This is called transmucosal absorption and results in onset 3–5x faster than a swallowed capsule, which must survive stomach acid and liver metabolism before entering circulation.
Gingerols and shogaols (the active compounds in ginger) bind to and inhibit 5-HT3 (serotonin) receptors in the gastrointestinal tract and the chemoreceptor trigger zone of the brain. This is the same receptor mechanism as ondansetron (Zofran), granisetron, and other prescription 5-HT3 antagonist antiemetics — which is why NCCN guidelines position ginger as a valid complementary adjunct to these medications. (Marx et al., 2017)
Shogaols also modulate Neurokinin-1 (NK1) receptors — the same pathway targeted by neurokinin antagonists such as aprepitant (Emend). NK1 receptors are particularly involved in delayed nausea (the nausea that persists days 2–5 after chemotherapy), where pharmaceutical coverage is often incomplete. Ginger's dual-receptor activity makes it especially valuable for this delayed window.
Ginger enhances gastric motility — the speed at which the stomach empties — reducing the "heavy," bloated feeling common during CINV. Chemotherapy often causes gastroparesis (slowed gastric emptying), which compounds nausea. Ginger's prokinetic action directly addresses this underlying mechanism.
Patients experiencing oral mucositis from chemotherapy cannot swallow capsules without significant pain. The dissolvable powder format allows full therapeutic-dose delivery without swallowing, making it accessible during the periods when traditional supplements cannot be used.
D-Ribose · 1,000mg per serving · ATP synthesis substrate · Pentose phosphate pathway · Mitochondrial energy recovery
Cytotoxic chemotherapy agents (platinum-based drugs, taxanes, anthracyclines) generate reactive oxygen species (ROS) that damage mitochondria — the cellular organelles responsible for ATP production. The result is profound mitochondrial energy depletion: cells cannot generate the ATP they need to function, which manifests as the heavy, persistent fatigue characteristic of cancer-related fatigue syndrome (CRFS).
D-Ribose is the five-carbon sugar that forms the backbone of ATP (adenosine triphosphate) and all adenine nucleotides (AMP, ADP, ATP). When D-Ribose is supplemented, it bypasses the rate-limiting enzymatic steps of glucose metabolism and enters the pentose phosphate pathway directly as ribose-5-phosphate — the immediate precursor to ATP synthesis.
Clinical research shows that D-Ribose supplementation accelerates ATP resynthesis in metabolically stressed tissue significantly faster than glucose alone — by a factor of 3–6x in depleted muscle tissue (Gross et al., 2003; Hellsten et al., 2004). This is not a stimulant effect — it is cellular energy restoration. No crash. No adenosine receptor blockade. Patients do not feel "artificially energized" — they feel less depleted.
Anti-na® SIPS uses Bioenergy Ribose® — a pharmaceutical-grade, patented D-Ribose manufactured to strict purity standards and used in the majority of clinical studies on D-Ribose supplementation. Not all D-Ribose supplements use the same grade of compound. Bioenergy Ribose® is the form with the established clinical track record, including the Teitelbaum et al. 2006 and Pliml et al. 1992 (The Lancet) studies.
Nausea and fatigue are not separate symptoms during chemotherapy — they are a cycle. Nausea triggers the body's protective stress response, diverting energy away from normal cellular functions. This energy diversion depletes ATP stores faster, deepening fatigue. The fatigue then impairs the body's ability to regulate gut motility and serotonin signaling, making nausea worse. SIPS addresses both ends of this cycle simultaneously: ginger calms the 5-HT3 and NK1 receptor signaling driving nausea, while D-Ribose restores the ATP stores that nausea and treatment have depleted. Treating one without the other leaves the cycle incomplete.
* These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Anti-na® SIPS is manufactured in an FDA-registered facility in Irvine, California under current Good Manufacturing Practice (cGMP) standards. FDA registration means the facility is subject to FDA inspection and must meet federal manufacturing standards for dietary supplements.
Each batch is tested against the World Anti-Doping Agency (WADA) list of prohibited substances. This is particularly relevant for oncology patients who may be participating in research protocols or clinical trials that prohibit certain supplements.
Anti-na® SIPS is a dietary supplement regulated under the Dietary Supplement Health and Education Act (DSHEA). It does not require an IND or NDA. The product is intended to complement — not replace — prescribed medical treatment. All claims comply with FTC and FDA guidelines for dietary supplements.
See the full study library or request a clinical one-pager for your practice.